JP2007523650A - 転移を阻害するための方法および組成物 - Google Patents

転移を阻害するための方法および組成物 Download PDF

Info

Publication number
JP2007523650A
JP2007523650A JP2006553317A JP2006553317A JP2007523650A JP 2007523650 A JP2007523650 A JP 2007523650A JP 2006553317 A JP2006553317 A JP 2006553317A JP 2006553317 A JP2006553317 A JP 2006553317A JP 2007523650 A JP2007523650 A JP 2007523650A
Authority
JP
Japan
Prior art keywords
antibody
metastatic
cell
activated
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006553317A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007523650A5 (https=
Inventor
ブルンヒルド フェルディング−ハーバーマン，
キム ディー． ジャンダ，
アラン サベン，
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2007523650A publication Critical patent/JP2007523650A/ja
Publication of JP2007523650A5 publication Critical patent/JP2007523650A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2848—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2006553317A 2004-02-13 2005-02-14 転移を阻害するための方法および組成物 Withdrawn JP2007523650A (ja)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US54480704P 2004-02-13 2004-02-13
US62672604P 2004-11-10 2004-11-10
US11/056,825 US7271245B2 (en) 2004-02-13 2005-02-11 Methods and compositions for inhibition of metastasis
PCT/US2005/004612 WO2005091805A2 (en) 2004-02-13 2005-02-14 Methods and compositions for inhibition of metastasis

Publications (2)

Publication Number Publication Date
JP2007523650A true JP2007523650A (ja) 2007-08-23
JP2007523650A5 JP2007523650A5 (https=) 2008-04-03

Family

ID=35056641

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006553317A Withdrawn JP2007523650A (ja) 2004-02-13 2005-02-14 転移を阻害するための方法および組成物

Country Status (5)

Country Link
US (2) US7271245B2 (https=)
EP (1) EP1725111A4 (https=)
JP (1) JP2007523650A (https=)
CA (1) CA2559480A1 (https=)
WO (1) WO2005091805A2 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508738A (ja) * 2007-12-26 2011-03-17 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８発現腫瘍細胞のターゲティングを向上させる方法及び剤
US9593166B2 (en) 2013-03-14 2017-03-14 Bayer Healthcare Llc Monoclonal antibodies against antithrombin β

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003256299A1 (en) * 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
AU2006270009A1 (en) * 2005-07-18 2007-01-25 Amgen Inc. Human anti-B7RP1 neutralizing antibodies
US20100104572A1 (en) * 2006-11-02 2010-04-29 Sylvie Luria Methods for screening for therapeutic molecules and use of the molecules therefrom
US7943728B2 (en) * 2006-12-26 2011-05-17 National Cheng Kung University Disintegrin variants and their use in treating osteoporosis-induced bone loss and angiogenesis-related diseases
WO2009042917A1 (en) * 2007-09-28 2009-04-02 The General Hospital Corporation Methods and compositions for antibody production
WO2009070753A2 (en) * 2007-11-28 2009-06-04 The Scripps Research Institute Bivalent single chain fv antibody compositions that specifically bind to integrin receptor on a metastatic cell in a mammalian subject
WO2009114816A2 (en) * 2008-03-14 2009-09-17 The Board Of Trustees Of The University Of Illinois Therapeutic cancer antigens
WO2010017083A1 (en) * 2008-08-04 2010-02-11 Wayne State University Methods of treating cancer with cd11b antibodies
US11180812B2 (en) 2012-08-17 2021-11-23 Cornell University Use of DNA in circulating exosomes as a diagnostic marker for metastatic disease
PH12022550138A1 (en) 2013-03-13 2023-03-06 Amgen Inc Proteins specific for baff and b7rp1 and uses thereof
US9458246B2 (en) 2013-03-13 2016-10-04 Amgen Inc. Proteins specific for BAFF and B7RP1
CN105793705A (zh) * 2013-09-30 2016-07-20 X博迪公司 抗原受体的筛选测试
US10844436B2 (en) 2014-04-01 2020-11-24 Cornell University Use of double-stranded DNA in exosomes: a novel biomarker in cancer detection
US11397182B2 (en) 2014-10-07 2022-07-26 Cornell University Methods for prognosing and preventing metastatic liver disease
US11971402B2 (en) 2015-04-24 2024-04-30 Cornell University Methods and reagents for determination and treatment of organotropic metastasis
WO2019241847A1 (en) * 2018-06-22 2019-12-26 Baker Heart and Diabetes Institute A therapeutic gpiib/iiia binding-protein drug conjugate and use thereof
WO2020176605A1 (en) * 2019-02-26 2020-09-03 The University Of Vermont And State Agricultural College Antibodies to neoantigens and uses thereof
AR124414A1 (es) 2020-12-18 2023-03-22 Century Therapeutics Inc Sistema de receptor de antígeno quimérico con especificidad de receptor adaptable

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9125979D0 (en) * 1991-12-06 1992-02-05 Wellcome Found Antibody
EP0633945B1 (en) 1992-04-03 1998-12-30 Genentech, Inc. ANTIBODIES TO ALPHAvBETA3 INTEGRIN
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
KR0119887B1 (ko) 1994-06-08 1997-10-30 김광호 반도체 메모리장치의 웨이퍼 번-인 테스트 회로
US6596850B1 (en) 1998-01-30 2003-07-22 Ixsys, Incorporated Anti-αv3β3 recombinant human antibodies, nucleic acids encoding same
WO1998046265A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Methods for using antagonistic anti-avb3 integrin antibodies
CA2284726A1 (en) 1997-04-11 1998-10-22 G.D. Searle & Co. Antagonistic anti-avb3 integrin antibodies
US6406693B1 (en) 1998-07-13 2002-06-18 Board Of Regents, The University Of Texas System Cancer treatment methods using antibodies to aminophospholipids
AU768329B2 (en) * 1998-12-04 2003-12-11 Novartis Ag Methods and compositions useful for targeting activated vitronectin receptor alphavbeta3
US6531580B1 (en) 1999-06-24 2003-03-11 Ixsys, Inc. Anti-αvβ3 recombinant human antibodies and nucleic acids encoding same
US20020025510A1 (en) 2000-07-26 2002-02-28 Strongin Alex Y. Screening methods based on superactivated alpha V beta 3 integrin
AU2002337954C1 (en) 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
AU2003217930A1 (en) 2002-03-04 2003-09-22 Medimmune, Llc The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2011508738A (ja) * 2007-12-26 2011-03-17 バイオテスト・アクチエンゲゼルシヤフト Ｃｄ１３８発現腫瘍細胞のターゲティングを向上させる方法及び剤
US9446146B2 (en) 2007-12-26 2016-09-20 Biotest Ag Methods and agents for improving targeting of CD138 expressing tumor cells
US9593166B2 (en) 2013-03-14 2017-03-14 Bayer Healthcare Llc Monoclonal antibodies against antithrombin β
US9908942B2 (en) 2013-03-14 2018-03-06 Bayer Healthcare, Llc Monoclonal antibodies against antithrombin β
US10144784B2 (en) 2013-03-14 2018-12-04 Bayer Healthcare Llc Monoclonal antibodies against antithrombin beta

Also Published As

Publication number Publication date
WO2005091805A3 (en) 2006-09-08
US7271245B2 (en) 2007-09-18
US20090117096A1 (en) 2009-05-07
CA2559480A1 (en) 2005-10-06
US20050255109A1 (en) 2005-11-17
WO2005091805A2 (en) 2005-10-06
EP1725111A2 (en) 2006-11-29
EP1725111A4 (en) 2008-08-06

Similar Documents

Publication Publication Date Title
US20090117096A1 (en) Methods and compositions for inhibition of metastasis
CN104130329B (zh) Trail受体结合剂和其用途
RU2573897C2 (ru) Антитела к cxcr4 и их применение для лечения рака
JP5959576B2 (ja) ブドウ球菌に対する殺活性を有するヒトの結合分子及びその使用方法
JP5586952B2 (ja) 腸球菌に対する殺活性を有するヒトの結合分子及びその使用方法
JP5086430B2 (ja) 血管内皮成長因子（ｖｅｇｆ）受容体を中和するヒトモノクローナル抗体及びその用途
KR20210040827A (ko) 항 tigit 항체 및 그 용도
JP5328156B2 (ja) オンコスタチンｍレセプターに対する抗体
JP2009527500A (ja) 免疫機能を改善するための方法および哺乳動物対象における疾患の防止または処置のための方法
JP2009533028A (ja) 新生物疾患の治療のための抗体組成物および方法
JP4660189B2 (ja) 抗血小板自己抗体およびそのインヒビターに関連する組成物、方法およびキット
US8722587B2 (en) Single chain fragment variable antibody libraries and uses thereof
CA2597717A1 (en) Antibodies against cxcr4 and methods of use thereof
KR20100051676A (ko) 종양 전이의 신생혈관과 관련된 피브리노겐의 ｅｄ-ａ 항원
US20080267981A1 (en) Compositions and Methods for Delivery of Antitumor Agents
JP2024502091A (ja) Ｐｄ－１結合分子およびその使用
JP2022514786A (ja) Ｍｕｃ１８に特異的な抗体
JP2021517816A (ja) 抗ポリシアル酸抗体およびその使用
CN121045380A (zh) Cd19结合分子及其用途
JP2025540215A (ja) Ｃｄ４７遮断剤と抗ｂｃｍａ／抗ｃｄ３二重特異性抗体との組合せ療法
CN120795148A (zh) Cd22结合分子及其用途
CN107108736A (zh) Trail受体结合剂及其用途
AU2012244351A1 (en) Antibodies binding to the extracellular domain of the Receptor Tyrosine Kinase ALK

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080213

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080213

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20101027